Premium
Mesenchymal Stromal Cell‐Mediated Treatment of Local and Systemic Inflammation through the Triggering of an Anti‐Inflammatory Response
Author(s) -
Martinez Jonathan O.,
Evangelopoulos Michael,
Brozovich Ava A.,
Bauza Guillermo,
Molinaro Roberto,
Corbo Claudia,
Liu Xuewu,
Taraballi Francesca,
Tasciotti Ennio
Publication year - 2021
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202002997
Subject(s) - mesenchymal stem cell , inflammation , homing (biology) , drug delivery , stromal cell , drug , cancer research , materials science , immunology , medicine , pharmacology , microbiology and biotechnology , biology , nanotechnology , ecology
The emergence of cell‐based therapeutics, specifically the use of mesenchymal stromal/stem cells (MSCs), stands to significantly affect the future of targeted drug delivery technologies. MSCs represent a unique cell type, offering more than only regenerative potential but also site‐specific inflammatory targeting and tissue infiltration. In this study, a versatile multicomponent delivery platform, combining MSC tropism with multistage nanovector (MSV)‐mediated payload delivery, is debuted. It is demonstrated that the incorporation of drug‐loaded MSVs bestows MSCs with the ability to transport anti‐inflammatory payloads, achieving a fivefold increase in payload release without negatively impacting cellular functions, viability, extravasation, and inflammatory homing. When incorporated within MSCs, MSVs avoid rapid sequestration by filtering organs and conserve a 15‐fold increase in local inflammatory targeting compared to healthy ears. Furthermore, this MSC‐mediated MSV platform (M&Ms) rapidly triggers a 4.5‐fold reduction of local inflammation compared to free drug and extends survival to 100% of treated mice in a lethal model of systemic inflammation.